Magnolia Medical Technologies
Magnolia Medical Technologies is the inventor of the Steripath Initial Specimen Diversion Device clinically proven to reduce false-positive blood culture contamination rates and false-positive CLABSIs to zero or near zero. Steripath is the only FDA 510(k)-cleared device indicated to reduce false-positive blood culture contaminations and is the only device to meet the ENA Clinical Practice Guidelines and INS Standard for >1/0 mL diversion volume. Learn how Steripath can impact your hospital by visiting our website.
Set a new standard with Steripath today.
- Reduction in false-positive up to 100%
- 10-Month sustained contamination rate as low as 0.0%
- Positive predictive value as high as 97%
- Reduction in vancomycin DOT as much as 37%
- Reduction in false-positive CLABSIs
- Shortened length of stay by an average of 2-2.4 days
- Reduce HAIs/HACs by as much as 23%
- Decrease annual costs by an average of $1.9M
*Reference available upon request
Brands: Steripath Gen2 Initial Specimen Diversion Device
Steripath Gen2 Initial Specimen Diversion Device with Integrated Syringe
Steripath Micro Initial Specimen Diversion Device